Coverage dated October 1, 2026

New triple agonist drug produces substantial weight loss in diabetic patients

Headline from MedicalXpress

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and appearing in The Lancet shows that treatment with the new triple agonist therapy retatrutide results in substantial weight loss and improvements in bloo…

MedicalXpress's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

2 articles, oldest first.

MedicalXpress
New triple agonist drug produces substantial weight loss in diabetic patients (opens MedicalXpress)
Published Oct 1, 2026
MedicalXpress's feed description
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and appearing in The Lancet shows that treatment with the new triple agonist therapy retatrutide results in substantial weight loss and improvements in bloo…
New York Post
‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight (opens New York Post)
Published Oct 1, 2026
New York Post's feed description
The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early next year.